Poinciana Advisors Group LLC Invests $363,000 in Eli Lilly and Company (NYSE:LLY)

Poinciana Advisors Group LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 440 shares of the company's stock, valued at approximately $363,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Peddock Capital Advisors LLC lifted its holdings in Eli Lilly and Company by 0.5% during the first quarter. Peddock Capital Advisors LLC now owns 5,124 shares of the company's stock valued at $4,232,000 after purchasing an additional 23 shares during the last quarter. Cooper Capital Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at about $205,000. Ascent Capital Management LLC raised its stake in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after acquiring an additional 12 shares in the last quarter. Leavell Investment Management Inc. boosted its position in Eli Lilly and Company by 17.3% during the first quarter. Leavell Investment Management Inc. now owns 7,547 shares of the company's stock valued at $6,233,000 after buying an additional 1,113 shares during the period. Finally, Quotient Wealth Partners LLC increased its stake in Eli Lilly and Company by 6.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,352 shares of the company's stock worth $2,768,000 after purchasing an additional 198 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on LLY. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim reissued a "buy" rating and set a $936.00 price target on shares of Eli Lilly and Company in a research report on Friday, June 20th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,012.22.

Eli Lilly and Company Price Performance

Shares of LLY traded up $3.31 during mid-day trading on Thursday, hitting $790.23. The company's stock had a trading volume of 3,128,711 shares, compared to its average volume of 3,670,296. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market capitalization of $748.93 billion, a P/E ratio of 64.30, a P/E/G ratio of 1.15 and a beta of 0.40. The firm has a 50-day simple moving average of $767.12 and a 200 day simple moving average of $800.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the business posted $2.58 EPS. The business's quarterly revenue was up 45.2% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.